Prothena | PRTA - Operating Profit


Prothena reported $-39.76M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Akebia Therapeutics USD 13.51M 27.82M Mar/2025
ALKERMES USD 89.08M 3.9M Sep/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amgen USD 3.96B 464M Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Exelixis USD 235.91M 20.45M Dec/2025
Immunic USD -25.73M 2.91M Sep/2024
Incyte USD 383.88M 47.43M Dec/2025
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
MacroGenics USD 18.64M 55.4M Sep/2025
Nektar Therapeutics USD -34.34M 15.43M Sep/2024
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Prothena USD -39.76M 12.25M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025
Xoma USD -15.64M 5.56M Sep/2024